Gracell September 26th, Zhuyun Health (09955.HK) announced that the independently developed diabetes digital pharmaceutical product ClouDT-01 has recently been approved by the Zhejiang Province Pharmaceutical Supervision and Administration Bureau in China, and has obtained its issued Chinese medical instruments registration certificate (Zhejiang Medical Device Registration No. 20242211785).
The announcement stated that ClouDT-01 is an important product in the group's digital pharmaceutical research and development pipeline. Relying on the company's advanced artificial intelligence model, comprehensive diabetes service management database, and rich clinical experience in diabetes, the product uses chain technology to deeply analyze the entire process of diabetes diagnosis and treatment, accurately positioning unmet needs of traditional treatments. Through dynamic graphics and real-time management, ClouDT-01 aims to further benefit diabetes patients clinically. The company is committed to developing globally leading excellent digital health services and products, thereby improving the accessibility and affordability of medical care services. The company adheres to the mission of "bringing digital health into thousands of households," actively responding to national policies and the goal of "Health China 2030," promoting the implementation of innovative technologies related to chronic disease management, in order to provide high-quality digital health services and products, benefiting more patients with chronic diseases.
